REG - Eco Animal Health Gp - Full Year Trading Update

ECO Animal HealthAnnouncement

Yesterday 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260319:nRSS2959Xa&default-theme=true

RNS Number : 2959X  Eco Animal Health Group PLC  19 March 2026

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE
INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO.
596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT
THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

19 March 2026

ECO Animal Health Group plc

("ECO" or the "Company")

 

Full Year Trading Update

Continued strong momentum in H2 with improved margins outperforming market
expectations

 

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces the following unaudited trading update
for the year ending 31 March 2026.

 

As previously announced, trading in the first half of this financial year was
significantly stronger compared to the same period last year. This trend has
continued to year end with an expected year-on-year increase in revenue of
c.8%, slightly ahead of market expectations(1) (2025: £79.6 million). Revenue
growth has been particularly strong in North America and Latin America,
despite currency headwinds and tariff challenges.

 

The Company also expects to report improved gross margins for the year,
primarily driven by improved product pricing and cost of goods. The combined
effect of the stronger revenue and margins is expected to result in a material
increase in adjusted EBITDA over the prior year (2025: £7.3m) with adjusted
EBITDA also materially ahead of market expectations.(1) The final outcome for
the full year will be subject to the usual audit process, including the
customary assessment of balance sheet provisioning.

 

The Company expects to report its audited full year results in early July.

 

(1) The consensus market expectations for revenue and adjusted EBITDA for the
year ending 31 March 2026 are £83.5m and £7.6m respectively.

 

-Ends-

Contacts

                                                                020 8447 8899

 ECO Animal Health Group plc

 David Hallas (Chief Executive Officer)

 Christopher Wilks (Chief Financial Officer)

 ICR Healthcare (Financial PR)                                  020 3709 5700

 Mary-Jane Elliott

 Jessica Hodgson

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Philip Davies

 Jalini Kalaravy

 Samed Ethemi

 Panmure Liberum (Joint Broker)                                 020 3100 2000

 Emma Earl

 Will Goode

 Mark Rogers

 Rupert Dearden

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

Our lead product, Aivlosin(®) is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFIFVRVVIALIR



            Copyright 2019 Regulatory News Service, all rights reserved